HC Wainwright reiterates Buy on Neurogene, keeps $70 target
HC Wainwright & Co. analyst Mitchell S. Kapoor has reiterated a Buy rating for Neurogene (NASDAQ: NGNE) and maintained a price target of $70.
*this image is generated using AI for illustrative purposes only.
HC Wainwright & Co. analyst Mitchell S. Kapoor has reaffirmed a Buy rating for Neurogene (NASDAQ: NGNE) while maintaining a price target of $70. The endorsement reflects continued confidence in the company's prospects.
Analyst Recommendation
Mitchell S. Kapoor, an analyst at HC Wainwright & Co., reiterated the firm's positive stance on Neurogene. The rating and price target remain unchanged following the review.
| Firm | Analyst | Rating | Price Target |
|---|---|---|---|
| HC Wainwright & Co. | Mitchell S. Kapoor | Buy | $70 |
What upcoming clinical milestones could drive Neurogene's stock toward the $70 price target?
How might recent advancements in gene therapy impact Neurogene's competitive positioning?
What are the potential regulatory hurdles Neurogene could face in the near term?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
